Literature DB >> 25791779

Are asthmatics enrolled in randomized trials representative of real-life outpatients?

Salvatore Battaglia1, Marco Basile, Mario Spatafora, Nicola Scichilone.   

Abstract

BACKGROUND/
OBJECTIVE: This study was aimed at exploring to what extent populations enrolled in randomized controlled trials (RCTs) of inhalation combination treatment for mild/moderate asthma in adults are fully representative of 'real-life' populations. The following is a retrospective analysis of the clinical records of outpatient subjects with an ascertained diagnosis of asthma.
METHODS: A retrospective analysis was performed. Stable conditions, such as smoking habit and chronic diseases other than asthma, were identified as exclusion criteria for RCTs. The selected criteria were then applied to asthmatic outpatients, yielding a population that was potentially eligible for RCTs.
RESULTS: Out of 1,909 subjects, 824 (43.2%) met at least one of the exclusion criteria for RCTs. Cigarette smoking (occurring in 34.3% of the entire population), lung diseases other than asthma (5.0%), anxiety and depression (3.3%), arrhythmias (2.3%), and coronary artery disease (1.2%) would have been the most frequent causes for exclusion from RCTs. The proportion of patients excluded from RCTs appears to increase with age, reaching 57.1% in patients aged >85 years.
CONCLUSIONS: In a real-life setting, >40% of subjects with mild/moderate asthma are currently treated by protocols based on the results of RCTs for which they would not have been eligible. This proportion increases in elderly patients with comorbidities. These findings limit the generalizability of RCTs and advocate that complementary pragmatic studies be conducted.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2015        PMID: 25791779     DOI: 10.1159/000375314

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  17 in total

1.  An Official American Thoracic Society Workshop Report: Evaluation and Management of Asthma in the Elderly.

Authors:  Gwen S Skloot; Paula J Busse; Sidney S Braman; Elizabeth J Kovacs; Anne E Dixon; Carlos A Vaz Fragoso; Nicola Scichilone; Y S Prakash; Christina M Pabelick; Sameer K Mathur; Nicola A Hanania; Wendy C Moore; Peter G Gibson; Susan Zieman; Betina B Ragless
Journal:  Ann Am Thorac Soc       Date:  2016-11

Review 2.  Leukotriene Receptor Antagonists for the Treatment of Asthma in Elderly Patients.

Authors:  Hoang Kim Tu Trinh; Ga-Young Ban; Ji-Ho Lee; Hae-Sim Park
Journal:  Drugs Aging       Date:  2016-10       Impact factor: 3.923

Review 3.  Routine Use of Budesonide/Formoterol Fixed Dose Combination in Elderly Asthmatic Patients: Practical Considerations.

Authors:  Nicola Scichilone; Fulvio Braido; Federico Lavorini; Mark L Levy; Omar S Usmani
Journal:  Drugs Aging       Date:  2017-05       Impact factor: 3.923

Review 4.  Pharmacological Management of Elderly Patients with Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome: Room for Speculation?

Authors:  Daniela Castiglia; Salvatore Battaglia; Alida Benfante; Claudio Sorino; Nicola Scichilone
Journal:  Drugs Aging       Date:  2016-06       Impact factor: 3.923

Review 5.  Pharmacotherapy in the management of asthma in the elderly: a review of clinical studies.

Authors:  Mi-Yeong Kim; Woo-Jung Song; Sang-Heon Cho
Journal:  Asia Pac Allergy       Date:  2016-01-27

6.  Eligibility of real-life patients with COPD for inclusion in RCTs: a commentary.

Authors:  Salvatore Battaglia; Nicola Scichilone
Journal:  Respir Res       Date:  2017-01-05

Review 7.  Use of ICS/LABA (extra-fine and non-extra-fine) in elderly asthmatics.

Authors:  Alida Benfante; Marco Basile; Salvatore Battaglia; Mario Spatafora; Nicola Scichilone
Journal:  Ther Clin Risk Manag       Date:  2016-10-14       Impact factor: 2.423

8.  Oral Corticosteroids Dependence and Biologic Drugs in Severe Asthma: Myths or Facts? A Systematic Review of Real-World Evidence.

Authors:  Luigino Calzetta; Marina Aiello; Annalisa Frizzelli; Giuseppina Bertorelli; Paola Rogliani; Alfredo Chetta
Journal:  Int J Mol Sci       Date:  2021-07-01       Impact factor: 5.923

Review 9.  Asthma in the elderly: a different disease?

Authors:  Salvatore Battaglia; Alida Benfante; Mario Spatafora; Nicola Scichilone
Journal:  Breathe (Sheff)       Date:  2016-03

Review 10.  Drop-out rate among patients treated with omalizumab for severe asthma: Literature review and real-life experience.

Authors:  M Caminati; G Senna; G Stefanizzi; R Bellamoli; S Longhi; F Chieco-Bianchi; G Guarnieri; S Tognella; M Olivieri; C Micheletto; G Festi; E Bertocco; M Mazza; A Rossi; A Vianello
Journal:  BMC Pulm Med       Date:  2016-08-25       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.